AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

Introduction: Cervical dystonia (CD) is a neurologic movement disorder with potentially disabling effects and significant impact on quality of life of those affected. AbobotulinumtoxinA (aboBoNT-A) was initially approved for a dilution of 500 U/1 mL and subsequently for a dilution of 500 U/2 mL, pro...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Mark F. Lew, Robert A. Hauser, Stuart H. Isaacson, Daniel Truong, Atul T. Patel, Allison Brashear, William Ondo, Pascal Maisonobe, Khashayar Dashtipour, Laxman Bahroo, Stefan Wietek
Format: article
Langue:EN
Publié: Elsevier 2021
Sujets:
Accès en ligne:https://doaj.org/article/1b10f3346552463da42e87acfb171361
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!